替吉奥与5-氟尿嘧啶联合奥沙利铂治疗晚期胃癌的临床疗效及安全性分析

Clinical efficacy and safety of S-1 with 5-fluorouracil and oxaliplatin in patients with advanced gastric cancer

目的分析替吉奥与5-氟尿嘧啶联合奥沙利铂治疗晚期胃癌的临床疗效及安全性。方法选取2011年1月至2014年7月间收治的90例晚期胃癌患者,采取随机数字表法分为对照组和试验组,每组45例。对照组给予5-氟尿嘧啶、奥沙利铂及亚叶酸钙治疗,试验组给予替吉奥联合奥沙利铂治疗,比较两组患者的临床疗效及不良反应。结果试验组患者的有效率和临床获益率分别为44.4%和91.1%,对照组分别为31.1%和75.6%,差异均有统计学意义(均P<0.05)。试验组与对照组在血细胞减少、血小板减少、恶心呕吐、贫血、外周神经毒性、腹泻及口腔黏膜炎方面差异均有统计学意义(均P<0.05)。结论采用替吉奥联合奥沙利铂治疗晚期胃癌的临床疗效较为确切,不良反应较少,安全性较高,值得推广。

Objective To explore and analyze the clinical efficacy and safety of S-1 with 5-fluorouracil and oxaliplatin therapy of advanced gastric cancer.Methods Ninty cases with advanced gastric cancer in Xuzhou Medical College Affiliated Hospital from January 2011 to July 2014 were admitted to this study.They were randomly divided into control group and experimental group,45 cases in each group.The control group received 5-fluorouracil,oxaliplatin and leucovorin;The experimental group received Gio and oxaliplatin treatment.The clinical efficacy and adverse reactions were observed.Results The experimental group and the control group showed significant differences in efficient and clinical benefit rate（x2=4.23,P 〈 0.05;x2= 4.98,P 〈 0.05）.The experimental group and control group also showed significant differences in pancytopenia,thrombocytopenia,nausea,vomiting,anemia,peripheral neurotoxicity,diarrhea and oral mucositis（x2= 4.51,P 〈 0.05;x2= 4.99,P 〈 0.05;x2= 4.41,P 〈 0.05;x2= 4.47,P 〈 0.05;x2= 4.19,P 〈 0.05;x2= 3.96,P 〈 0.05）.Conclusion For patients with advanced gastric cancer,Gio plus oxaliplatin show better clinical efficacy,have less adverse reactions,with high security.